Futibatinib (Lytgobi)
Small molecule
Also known as TAS-120
Evidence outlook
Approved: Cholangiocarcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signalSingle-arm, accepted for approval (FDA label)
Also in development:Biliary Tract Cancer · Phase 3 · investigational in the US
Also approved (2)
- Conditional marketing authorisation: monotherapy for adult patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy (Lytgobi)
- Treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02052778 NCT02052778 · Cholangiocarcinoma The study was non-randomized, open-label, and had no placebo or active comparator arm; all participants received futibatinib. Although objective responses were reported, including a 41.7% response rate in the phase 2 cholangiocarcinoma cohort, a single-arm design cannot establish comparative efficacy or control for bias. This is exploratory, hypothesis-generating evidence rather than a controlled efficacy trial. Registry: NCT02052778 | 1/2 | Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD) (Cycle 1 (21-day cycle)); Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120 (Cycle 1 (21-day cycle)); Phase 1: Dose Expansion: Percentage of Participants With Objective Response (Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohorts); Phase 2: Percentage of Participants With Objective Response (Up to approximately 37.5 months (through cut-off date 29-May-2021)) 2020-10-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Biliary Tract Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Futibatinib (Lytgobi): this drug | Phase 3 | Small molecule | FGFR (FGFR1/2/3/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | Weak signal | NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | |
| Ivonescimab | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tovecimig | Phase 2/3 | Multispecific antibody | DLL4 x VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Phase 2 | Monoclonal antibody | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Futibatinib (Lytgobi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.